Antithrombotic Safety Linked to GFR
FONDAPARINUX may be safer than enoxaparin as treatment for non-ST-segment elevation acute coronary syndromes (ACS) in patients with renal dysfunction.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.